Last Update 10 May 26
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector.
Analyst Commentary
Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions. Price targets have moved both higher and lower in recent months, with most adjustments tied to updated models following Q4 results, revised revenue outlooks and evolving views on growth drivers such as GLP-1 related programs and multi condition offerings.
Bullish Takeaways
- Bullish analysts highlight Q4 results that included an 8% revenue beat and a US$7m EBITDA beat, which they view as evidence that Omda is executing against current guidance and supporting their higher fair value estimates.
- Some bullish analysts point to continued momentum across all programs and new product launches, arguing that this supports the case for a sustained growth profile that they believe is not fully reflected in current valuation multiples.
- Q4 revenue and member trends linked to GLP-1 adoption and multi condition adoption are cited as key growth drivers, with certain analysts suggesting these factors provide room for upside relative to Omda's fiscal 2026 revenue outlook.
- Several bullish analysts describe Omda as more than just a beneficiary of a rapidly evolving GLP-1 market. They emphasize a broader growth runway across programs that underpins their constructive stance on the stock's long term potential.
Bearish Takeaways
- Bearish analysts have reduced price targets, signaling concern that prior expectations may have been too optimistic relative to current guidance and sector valuation levels, even as they maintain generally positive ratings on the stock.
- Some research points to valuation pressure across the broader Healthcare Information Technology sector, which they argue is weighing on Omda's trading multiples and limiting near term upside in fair value assessments.
- Certain analysts describe Omda's outlook as including several pockets of conservatism. While this may be viewed as positive if execution is strong, it also reflects caution around how quickly revenue growth and profitability can translate into higher justified valuation.
- There is an active debate around how conservative Omda's 2026 guidance is, with more cautious analysts flagging the risk that current expectations for repeat outperformance could prove demanding if growth normalizes or macro conditions become less supportive.
What's in the News
- Omda plans to ask shareholders at the April 28, 2026 annual general meeting to approve formal articles of association for a nomination and remuneration committee, setting clear rules around purpose, composition, duties and independence. (Key Developments)
- The proposed nomination committee is set to have 3 to 5 members, with a majority independent of the board and management, and explicitly excludes the chief executive officer from membership. (Key Developments)
- Under the proposal, the nomination committee would recommend board members and set remuneration proposals for the board and the committee itself, with justifications and candidate information to be made available at least 2 weeks before relevant meetings. (Key Developments)
- Omda reiterated its 2026 earnings guidance, with expected revenue in the range of NOK 500 million to NOK 525 million. (Key Developments)
- The 2026 revenue guidance range of NOK 500 million to NOK 525 million has been repeated in multiple guidance updates, indicating consistency in management’s stated outlook. (Key Developments)
Valuation Changes
- Fair Value: NOK 57.0 is unchanged, indicating a stable central estimate for Omda's equity value.
- Discount Rate: The discount rate has fallen slightly from 9.20% to about 8.82%, reflecting a modestly lower required return in the updated model.
- Revenue Growth: The long term revenue growth assumption is essentially unchanged at about 4.77%.
- Net Profit Margin: The net profit margin assumption remains steady at about 7.72%.
- Future P/E: The future P/E multiple has edged down slightly from about 33.74x to 33.38x, suggesting a marginally lower valuation multiple applied to projected earnings.
Key Takeaways
- High reliance on public sector and Nordic-European contracts exposes Omda to risks from budget constraints, regulatory changes, and potential cuts in IT spending.
- Sustained competitiveness demands heavy investment in R&D and cyber compliance, which could hinder margin growth amid intensifying international competition.
- Strong recurring revenue, robust customer retention, digital health expansion, and strategic cost and M&A initiatives are driving Omda's sustainable growth and margin improvement.
Catalysts
About Omda- Provides software solutions for the healthcare and emergency response sector in Norway, Sweden, Denmark, Finland, and internationally.
- Investors may be overestimating Omda's ability to maintain strong revenue growth rates, as much of its expansion relies on ongoing digitization in healthcare and public investment, which can be challenged by potential macroeconomic pressures or austerity measures-raising the risk of future revenue disappointments if public sector IT spending slows.
- The company's heavy dependence on publicly funded, Nordic and European contracts creates long-term exposure to regulatory tightening and cyclically constrained government budgets, suggesting margins and recurring revenues could be impacted by compliance cost increases or contract cutbacks.
- Although the company highlights strong, resilient recurring revenues and successful margin expansion, the required pace of R&D and platform upgrades to remain competitive (including integration of AI and data analytics) may keep operating expenses higher for longer, compressing net margins over time.
- Market valuations may not fully account for Omda's vulnerability to increasing data privacy regulation complexity and the continually evolving cyber-threat landscape, both of which carry the potential for higher costs, reputational risks, and lower profitability in the future.
- Despite positive outlooks regarding geographic and product expansion, Omda faces intensifying competition from large established international health tech firms and startups; this could erode its pricing power and market share, placing future revenue and earnings growth at risk if growth expectations are priced for near-perfection.
Omda Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Omda's revenue will grow by 4.8% annually over the next 3 years.
- Analysts assume that profit margins will increase from 1.3% today to 7.7% in 3 years time.
- Analysts expect earnings to reach NOK 44.0 million (and earnings per share of NOK 2.08) by about May 2029, up from NOK 6.6 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 34.2x on those 2029 earnings, down from 121.0x today. This future PE is lower than the current PE for the NO Healthcare Services industry at 377.6x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 8.82%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The aging global population and increasing demand for efficient, digitalized healthcare solutions are likely to drive sustained volume growth for Omda, as evidenced by their expanding footprint in specialized sectors (e.g., Emergency and fertility areas), supporting long-term revenue stability and growth.
- The company's highly diversified revenue base-over 750 active contracts across 26 countries, with >79% recurring revenues and ultra-low churn (<2%)-demonstrates strong customer retention, resilience, and predictability, countering risks of revenue decline.
- Ongoing digital transformation in healthcare, including adoption of patient-centric IT platforms and integration of AI-driven modules, positions Omda well to capture both organic growth (guided at 5–10% per year) and higher-margin value-added sales, enhancing future gross margins and earnings.
- Strategic cost efficiencies (such as COGS reduction toward 5%, selective FTE reductions, and productivity gains via AI-assisted development) have led to significant EBITDA margin improvement (from 12% to 20% YoY, aiming for 28%–32% in 2026), supporting robust future net margin and earnings expansion.
- Prudent, disciplined M&A activity-focused on acquiring complementary software and domain expertise within existing verticals-and the ability to leverage favorable market conditions for acquisitions (lower upfront cash, earnouts) suggest further scalable inorganic growth, diversification, and upside for both revenue and margins.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of NOK57.0 for Omda based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be NOK570.0 million, earnings will come to NOK44.0 million, and it would be trading on a PE ratio of 34.2x, assuming you use a discount rate of 8.8%.
- Given the current share price of NOK39.0, the analyst price target of NOK57.0 is 31.6% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Omda?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.